RecruitingNCT05204199

Role of Microbiome in BCG Responsiveness Prediction

Towards Individualization of Bladder Cancer Therapy: the Role of Microbiome in BCG Responsiveness Prediction

Sponsor

Cédric Poyet

Enrollment

120 participants

Start Date

Feb 22, 2022

Study Type

OBSERVATIONAL

Conditions

Bladder Cancer Microbiome

Summary

Our primary aim is to investigate the use of microbial profile from the bladder and the feces of NMIBC patients as a predicting tool for therapy response prior to BCG administration. Our second aim is to collect additional samples (blood, instrumented urine, bladder tissue, feces) to establish a local biobank for future microbiome projects.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether the gut microbiome (the community of bacteria living in your digestive tract) influences how well BCG immunotherapy works for bladder cancer patients. **You may be eligible if...** - You are between 18 and 90 years old - You can understand and follow study procedures **You may NOT be eligible if...** - You have taken antibiotics in the past month - You have had chemotherapy or immunotherapy in the past 6 months - You are on immunosuppressive medications - You have a major medical condition (other than well-controlled ones like high blood pressure) - You have a condition known to significantly affect the gut microbiome Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.